Open Accessibility Menu

Coronavirus (COVID-19) Vaccine Update Click here to learn more.

For information about COVID-19 or to view additional resources, please click here.

Clinical Trial Information

A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS

Study Details

  1. Patients with chronic hand and foot dermatitis diagnosed at least 3 years prior to the screening visit for patients ≥18 years old, and at least 1 year prior to the screening visit for patients ≥12 to <18 years old.
     
  2. Patients with involvement of at least 2 anatomical areas at screening and baseline. These 2 anatomical areas could be both hands, 1 hand and 1 foot, or both feet.
     
  3. Patients need to have an IGA hand and foot score of 3 or 4 (moderate-to-severe disease) at screening and baseline.

Primary Sponsor:

Regeneron

Prinicipal Investigator:

Dr. Joseph Zahn

Contact Phone:

(202) 667-6160
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIENTS WITH MODERATE-TO-SEVERE ATOPIC HAND AND FOOT DERMATITIS ntolstoy@mfa.gwu.edu

Interested in More Information

  • Please enter your first name.
  • Please enter your last name.
  • This isn't a valid email address.
    Please enter your email address.
  • This isn't a valid phone number.
    Please enter your phone number.
    You entered an invalid number.
  • Please enter your address.
  • Please enter your city.
  • Please enter your state.
  • Please enter your zip code.
  • (All Uppercase. No Spaces)